Plain-English translation of NCT05620680 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
This trial is testing a new treatment called for people with T-cell lymphoma or leukemia that has come back or didn't respond to previous treatments. are immune cells that have been genetically modified in a laboratory to recognize and fight cancer cells. The study will look at whether this new treatment is safe and whether it actually works to help patients.
T-cell lymphomas and leukemias are aggressive cancers, and about half of patients relapse after their first treatment. When standard treatments fail, patients have very few good options left. This trial exists to offer a new approach for people whose cancer has not responded to conventional therapies.
You likely qualify if…
You likely don't qualify if…
If you qualify for this trial, doctors will collect some of your immune cells through a procedure called apheresis (similar to donating blood). These cells will be sent to a laboratory where they are modified to recognize and attack your cancer cells. The modified cells will then be grown in larger numbers and given back to you through infusion. You will be closely monitored during and after the treatment to watch for side effects and to see how well the treatment is working.
AI-generated summary from trial data · Jun 27, 2026 · Not medical advice
China
Sponsor
Shenzhen University General Hospital
Enrollment target
~20 participants
Started
October 2022
Primary completion
October 2026
Age range
18 Years – 75 Years
Last updated on clinicaltrials.gov in November 2022.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Yu Li, Dr
Shenzhen University General Hospital
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.